Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Rhumbline Advisers

Rhumbline Advisers boosted its stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 15.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 132,491 shares of the company’s stock after purchasing an additional 17,411 shares during the period. Rhumbline Advisers’ holdings in Lineage Cell Therapeutics were worth $132,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Fifth Third Wealth Advisors LLC bought a new stake in shares of Lineage Cell Therapeutics in the 1st quarter worth about $30,000. DCF Advisers LLC increased its holdings in Lineage Cell Therapeutics by 14.5% in the fourth quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock valued at $103,000 after buying an additional 12,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock valued at $239,000 after buying an additional 70,418 shares in the last quarter. Comerica Bank lifted its holdings in Lineage Cell Therapeutics by 84,745.8% during the 1st quarter. Comerica Bank now owns 250,295 shares of the company’s stock worth $370,000 after buying an additional 250,000 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Lineage Cell Therapeutics by 35.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock worth $435,000 after acquiring an additional 114,762 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Craig Hallum started coverage on shares of Lineage Cell Therapeutics in a research report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 price target on the stock.

Lineage Cell Therapeutics Stock Up 6.8 %

Shares of LCTX stock opened at $0.92 on Monday. The stock has a market cap of $173.73 million, a P/E ratio of -6.57 and a beta of 1.26. Lineage Cell Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. Lineage Cell Therapeutics had a negative return on equity of 36.30% and a negative net margin of 391.00%. The firm had revenue of $1.41 million for the quarter, compared to analysts’ expectations of $1.28 million. As a group, sell-side analysts predict that Lineage Cell Therapeutics, Inc. will post -0.12 EPS for the current fiscal year.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.